Sergey Yurasov
Director Técnico/Científico/I+D en BLACK DIAMOND THERAPEUTICS, INC. .
Fortuna: - $ al 30/04/2024
Cargos activos de Sergey Yurasov
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2022 | - |
Historial de carrera de Sergey Yurasov
Antiguos cargos conocidos de Sergey Yurasov.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
NUVATION BIO INC. | Director Técnico/Científico/I+D | 01/09/2019 | 01/02/2022 |
IMMUNE DESIGN CORP | Director Técnico/Científico/I+D | 04/10/2016 | 02/04/2019 |
The Rockefeller University | Corporate Officer/Principal | - | - |
Hoffman-La Roche, Inc. | Corporate Officer/Principal | - | - |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - | - |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
Formación de Sergey Yurasov.
Russian State Medical University | Doctorate Degree |
Research Institute for Pediatric Oncology | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Rusia | 3 |
Operativa
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 2 |
Sectorial
Health Technology | 7 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
NUVATION BIO INC. | Health Technology |
Empresas privadas | 4 |
---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Hoffman-La Roche, Inc. | Health Technology |
- Bolsa de valores
- Insiders
- Sergey Yurasov
- Experiencia